myBiometry

Executive Summary

myBiometry is a digital health startup focused on remote patient monitoring for chronic conditions, starting with asthma. The company leverages proprietary sensors to measure Fractional Exhaled Nitric Oxide (FeNO), a key biomarker for airway inflammation, enabling clinicians to track medication adherence and efficacy. By combining biomarker data with software analytics, myBiometry aims to improve asthma management and reduce exacerbations. Founded in 2019 and headquartered in San Francisco, the company operates in the AI/ML and digital health sectors. Its platform addresses a significant unmet need in chronic disease management, where remote monitoring can lower healthcare costs and improve patient outcomes. With asthma affecting millions globally, myBiometry's approach has the potential to disrupt traditional care models by providing objective, real-time data to guide treatment decisions. The company is at an early stage, with no disclosed funding or revenue, but its focus on a validated biomarker and digital health trend positions it for growth if it can secure regulatory clearance and commercial partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for FeNO sensor60% success
• Q2 2026Publication of clinical validation study results70% success
• Q3 2026Strategic partnership with a major pharma or device company for distribution55% success